Mesoridazine Oral Concentrate |
Serentil Oral Concetrate |
Clinical Trial: Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia
This study is currently recruiting patients.
Verified by National Taiwan University Hospital August 2004
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Oral Leukoplakia | Procedure: photodynamic therapy | Phase IV |
MedlinePlus related topics: Cancer; Cancer Alternative Therapies; Oral Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Secondary Outcomes: Regression of lesions
Expected Total Enrollment: 40
Study start: August 2004; Expected completion: July 2005
Last follow-up: June 2005; Data entry closure: June 2005
Eligibility
Inclusion Criteria:
- patients with leukoplakia or erythroleukoplakia
Exclusion Criteria:
- oral cancers
Location and Contact Information
Taiwan
National Taiwan University Hospital, Taipei, 100, Taiwan; Recruiting
Chun-Pin Chiang, DMSc 886-2-23123456 Ext. 6855 cpchiang@ha.mc.ntu.edu.tw
Chun-Pin Chiang, DMSc, Principal Investigator
Chun-Pin Chiang, DMSc, Principal Investigator, National Taiwan University Hospital
More Information
Last Updated: September 9, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00155337
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Mesoridazine Oral Concentrate (Drug Digest)
- Serentil Oral Concetrate (Drug Digest)

Not Signed In -


